Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Board Declares Dividend, Approves Friel as CEO

NEW YORK (GenomeWeb News) — PerkinElmer said yesterday that its board of directors has declared a quarterly dividend and, as expected, has elected President and COO Robert Friel to the post of CEO.
 
The company said the quarterly dividend of $.07 per share of common stock is payable on May 9 to all shareholders of record by the close of business on April 18.
 
In a move consistent with the company’s 2007 leadership succession plan, PerkinElmer also announced that Friel will become its new CEO on Feb. 1. Friel, who joined the company as chief financial officer in 1999, became vice chairman and president of the firm’s life and analytical sciences business in 2006. Last year, he was promoted to president and chief operating officer. He also will retain the title of president after assuming the role of CEO.
 
“Rob has a long track record of results in a wide variety of challenging roles and knows the company extremely well,” Gregory Summe, executive chairman of PerkinElmer’s board, said in a statement. “The board of directors and I believe that Rob is the right leader to drive PerkinElmer’s future growth and expansion, and look forward to his continued success.”

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.